Clinical trials

Two Combination Regimens Become NCCN‑Preferred First‑Line Options for EGFR‑Mutated Lung Cancer

Experts now individualize first‑line care by weighing TP53 co‑mutation, ctDNA clearance, intracranial data to choose between a chemo‑sparing antibody‑TKI or a chemo‑containing TKI regimen.